Does the media refer more to COLL or VKTX?

In the previous week, Viking Therapeutics had 8 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.75 beat Viking Therapeutics' score of 0.28 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to COLL or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.75 beat Tango Therapeutics' score of 0.35 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to COLL or ACAD?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 3 mentions for Collegium Pharmaceutical. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Collegium Pharmaceutical's score of 0.75 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COLL or NAMS?

In the previous week, Collegium Pharmaceutical and Collegium Pharmaceutical both had 3 articles in the media. Collegium Pharmaceutical's average media sentiment score of 0.75 beat NewAmsterdam Pharma's score of 0.51 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNLI or COLL?

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 3 mentions for Collegium Pharmaceutical and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.93 beat Collegium Pharmaceutical's score of 0.75 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Collegium Pharmaceutical (COLL) Competitors

$35.54 -0.54 (-1.50%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$35.53 -0.01 (-0.03%)

As of 07/20/2026 07:34 PM Eastern

Compare

COLL vs. VKTX, TNGX, ACAD, NAMS, and DNLI

Should you buy Collegium Pharmaceutical stock or one of its competitors? MarketBeat compares Collegium Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Collegium Pharmaceutical include Viking Therapeutics (VKTX), Tango Therapeutics (TNGX), ACADIA Pharmaceuticals (ACAD), NewAmsterdam Pharma (NAMS), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does Collegium Pharmaceutical compare to Viking Therapeutics?

Collegium Pharmaceutical (NASDAQ:COLL) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Collegium Pharmaceutical presently has a consensus price target of $57.50, suggesting a potential upside of 61.79%. Viking Therapeutics has a consensus price target of $93.60, suggesting a potential upside of 157.28%. Given Viking Therapeutics' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

76.0% of Viking Therapeutics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Collegium Pharmaceutical has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.42
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Collegium Pharmaceutical has a net margin of 9.41% compared to Viking Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Viking Therapeutics	N/A	-71.31%	-65.35%

In the previous week, Viking Therapeutics had 8 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.75 beat Viking Therapeutics' score of 0.28 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Viking Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Tango Therapeutics?

Collegium Pharmaceutical (NASDAQ:COLL) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Collegium Pharmaceutical presently has a consensus target price of $57.50, suggesting a potential upside of 61.79%. Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 53.06%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Collegium Pharmaceutical has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.42
Tango Therapeutics	$62.38M	63.86	-$101.59M	-$0.83	N/A

Collegium Pharmaceutical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Tango Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Tango Therapeutics	N/A	-41.54%	-33.44%

In the previous week, Tango Therapeutics had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.75 beat Tango Therapeutics' score of 0.35 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Tango Therapeutics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to ACADIA Pharmaceuticals?

Collegium Pharmaceutical (NASDAQ:COLL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 3 mentions for Collegium Pharmaceutical. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Collegium Pharmaceutical's score of 0.75 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Collegium Pharmaceutical's net margin of 9.41%. Collegium Pharmaceutical's return on equity of 95.18% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

ACADIA Pharmaceuticals has higher revenue and earnings than Collegium Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.42
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

Collegium Pharmaceutical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Collegium Pharmaceutical currently has a consensus price target of $57.50, indicating a potential upside of 61.79%. ACADIA Pharmaceuticals has a consensus price target of $32.94, indicating a potential upside of 31.29%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts plainly believe Collegium Pharmaceutical is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Collegium Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to NewAmsterdam Pharma?

Collegium Pharmaceutical (NASDAQ:COLL) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Collegium Pharmaceutical and Collegium Pharmaceutical both had 3 articles in the media. Collegium Pharmaceutical's average media sentiment score of 0.75 beat NewAmsterdam Pharma's score of 0.51 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 9.41% compared to NewAmsterdam Pharma's net margin of -943.23%. Collegium Pharmaceutical's return on equity of 95.18% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Collegium Pharmaceutical has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.42
NewAmsterdam Pharma	$22.50M	154.15	-$203.82M	-$1.79	N/A

Collegium Pharmaceutical currently has a consensus price target of $57.50, suggesting a potential upside of 61.79%. NewAmsterdam Pharma has a consensus price target of $49.42, suggesting a potential upside of 66.55%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Collegium Pharmaceutical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats NewAmsterdam Pharma on 11 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

92.9% of Denali Therapeutics shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Denali Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 3 mentions for Collegium Pharmaceutical and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.93 beat Collegium Pharmaceutical's score of 0.75 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics currently has a consensus target price of $35.08, indicating a potential upside of 53.20%. Collegium Pharmaceutical has a consensus target price of $57.50, indicating a potential upside of 61.79%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17

Collegium Pharmaceutical has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.00	-$512.54M	-$2.88	N/A
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.42

Collegium Pharmaceutical has a net margin of 9.41% compared to Denali Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Summary

Collegium Pharmaceutical beats Denali Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.17B	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	17.42	20.20	27.07	23.94
Price / Sales	1.48	340.68	515.91	90.33
Price / Cash	2.37	27.11	26.68	47.25
Price / Book	3.73	4.20	10.43	6.14
Net Income	$62.87M	$65.94M	$3.60B	$331.74M
7 Day Performance	1.48%	-3.05%	-1.20%	-1.82%
1 Month Performance	5.96%	-1.30%	1.12%	-1.45%
1 Year Performance	14.98%	15.22%	23.66%	16.32%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	2.612 of 5 stars	$35.54 -1.5%	$57.50 +61.8%	+13.9%	$1.17B	$780.57M	17.42	210	News Coverage
VKTX Viking Therapeutics	3.1072 of 5 stars	$38.12 -1.9%	$93.60 +145.5%	+13.7%	$4.51B	N/A	N/A	20
TNGX Tango Therapeutics	2.5351 of 5 stars	$28.36 -8.7%	$41.50 +46.3%	+306.8%	$4.49B	$62.38M	N/A	90
ACAD ACADIA Pharmaceuticals	4.7931 of 5 stars	$25.50 -2.7%	$32.94 +29.2%	+11.2%	$4.49B	$1.07B	11.59	510
NAMS NewAmsterdam Pharma	3.1984 of 5 stars	$33.28 -5.6%	$49.00 +47.2%	+33.6%	$4.12B	$22.50M	N/A	4	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. VKTX, TNGX, ACAD, NAMS, and DNLI

How does Collegium Pharmaceutical compare to Viking Therapeutics?

Summary

How does Collegium Pharmaceutical compare to Tango Therapeutics?

Summary

How does Collegium Pharmaceutical compare to ACADIA Pharmaceuticals?

Summary

How does Collegium Pharmaceutical compare to NewAmsterdam Pharma?

Summary

How does Collegium Pharmaceutical compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. VKTX, TNGX, ACAD, NAMS, and DNLI

How does Collegium Pharmaceutical compare to Viking Therapeutics?

Do analysts prefer COLL or VKTX?

Do institutionals & insiders hold more shares of COLL or VKTX?

Which has stronger valuation & earnings, COLL or VKTX?

Is COLL or VKTX more profitable?

Does the media refer more to COLL or VKTX?

Which has more volatility and risk, COLL or VKTX?

Summary

How does Collegium Pharmaceutical compare to Tango Therapeutics?

Do analysts recommend COLL or TNGX?

Which has stronger earnings & valuation, COLL or TNGX?

Which has more volatility and risk, COLL or TNGX?

Is COLL or TNGX more profitable?

Does the media refer more to COLL or TNGX?

Do institutionals and insiders have more ownership in COLL or TNGX?

Summary

How does Collegium Pharmaceutical compare to ACADIA Pharmaceuticals?

Does the media refer more to COLL or ACAD?

Is COLL or ACAD more profitable?

Which has higher valuation and earnings, COLL or ACAD?

Which has more volatility & risk, COLL or ACAD?

Do analysts recommend COLL or ACAD?

Do institutionals & insiders believe in COLL or ACAD?

Summary

How does Collegium Pharmaceutical compare to NewAmsterdam Pharma?

Does the media refer more to COLL or NAMS?

Do institutionals and insiders hold more shares of COLL or NAMS?

Is COLL or NAMS more profitable?

Which has stronger valuation and earnings, COLL or NAMS?

Do analysts recommend COLL or NAMS?

Which has more volatility and risk, COLL or NAMS?

Summary

How does Collegium Pharmaceutical compare to Denali Therapeutics?

Do institutionals & insiders have more ownership in DNLI or COLL?

Which has more volatility & risk, DNLI or COLL?

Does the media favor DNLI or COLL?

Do analysts prefer DNLI or COLL?

Which has preferable valuation and earnings, DNLI or COLL?

Is DNLI or COLL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools